Extending Indication: Role of Living Donor Liver Transplantation for Hepatocellular Carcinoma
|
|
- Alaina Stephens
- 5 years ago
- Views:
Transcription
1 LIVER TRANSPLANTATION 13:S48-S54, 27 SUPPLEMENT Extending Indication: Role of Living Donor Liver Transplantation for Hepatocellular Carcinoma Satoru Todo, 1 Hiroyuki Furukawa, 2 Mitsuhiro Tada, 3 and the Japanese Liver Transplantation Study Group 1 Department of General Surgery, Hokkaido University Graduate School of Medicine, 2 Department of Organ Transplantation and Regenerative Medicine, Hokkaido University Graduate School of Medicine, and 3 Research Section of Molecular Pathogenesis, Division of Cancer-Related Genes, Institute for Genetic Medicine, Hokkaido University, Sapporo, Japan KEY CONCEPTS Living donor liver transplantation. Indication of hepatocellular carcinoma. Milan criteria. United Network for Organ Sharing (UNOS) tumor staging. Alfa-fetoprotein (AFP). Protein induced by vitamin K absence or antagonism factor II (PIVKA II). Liver Transpl 13:S48-S54, AASLD. Hepatocellular carcinoma (HCC) is the fifth most common cause of malignant disease and the third cause of cancer-related mortality worldwide. Age-adjusted incidence is 14.9 per million in male and 5.5 per million in female subjects, and it is 5-6-fold higher in Asian countries than North America and Europe as a result of the endemic prevalence of hepatitis B virus (HBV) infection. In the United States, approximately 1, new cases occur annually, and it is estimated that the number will double over the next 2 decades because of increased hepatitis C virus (HCV) infection during 197s and 198s. Of the 5, individuals who die annually of end-stage liver disease in Japan, HCC accounts for 35, deaths, in spite of wide varieties of therapeutic modalities, including percutaneous ethanol injection, transarterial chemoembolization, microwave coagulation therapy, radiofrequency ablation, systemic chemotherapy, hepatic resection (Hx), and liver transplantation (LT). DISEASED DONOR LT LT theoretically offers cure for patients with HCC by achieving total removal of cancerous lesions and underlying HBV and HCV liver cirrhosis. Early experiences of deceased donor liver transplantation (DDLT) for HCC, however, were discouraging because of the higher recurrence rate and resulting decreased patient survival (Table 1). Thus, the detection of risk factors for recurrence and the selection criteria for HCC patients who would have less incidence of recurrence after DDLT were 2 important topics during early 199s. The Pittsburgh group determined that pathological risk factors consisted of lymph node metastasis, vascular invasion, and tumor number and size. On the basis of this and the other analysis, in 1996, the Milan criteria were proposed, which limit patients with HCC for DDLT. The criteria include solitary tumor up to 5 cm in diameter, or multiple nodules (fewer than 3), each 3 cm in diameter. Patients with extrahepatic spread and/or macroscopic vascular invasion of disease were not eligible for transplantation. Worldwide adoption of the Milan criteria as a standard improved 5-year patient survival by 3-7% (Table 1). Subsequently, slightly expanded criteria the University of California, San Francisco (UCSF), criteria were proposed. The UCSF criteria are as follows: solitary tumor 6.5 cm, or 3 nodules with the largest lesion 4.5 cm and total tumor diameter 8 cm. The UCSF criteria allowed 1- and 5-year patient survival of 9% and Abbreviations: HCC, hepatocellular carcinoma; HBV, hepatitis B virus; HCV, hepatitis C virus; LT, liver transplantation; Hx, hepatic resection; DDLT, deceased donor liver transplantation; UCSF, University of California, San Francisco; UNOS, United Network for Organ Sharing; MELD, Model for End-Stage Liver Disease; LDLT, living donor liver transplantation; DFS, disease-free survival; AFP, alfa-fetoprotein; PIVKA II, protein induced by vitamin K absence or antagonism factor II; A-P levels, AFP 2 ng/ml and PIVKA II 1 mau/ml. Address reprint requests to Satoru Todo, MD, Department of General Surgery, Hokkaido University Graduate School of Medicine, N-15, W-7, Kita-ku, Sapporo -8638, Japan. Telephone: ; FAX: ; stodo@med.hokudai.ac.jp DOI 1.12/lt Published online in Wiley InterScience ( S48 Liver Transplantation, Vol 13, No 11, Suppl 2 (November), 27: pp S48-S54
2 LDLT FOR HCC IN JAPAN S49 TABLE 1. Deceased Donor Liver Transplantation Before and After Implementation of Milan Criteria Transplantation n 5-yr survival rate (%) Recurrence (%) Deceased donor liver transplantation before Milan criteria Penn (1991) Ringe (1991) Iwatsuki (1991) Deceased donor liver transplantation after Milan criteria Mazzaferro (1996) (Milan criteria) * 8. Jonas (21) (Milan criteria) Figueras (21) ( 5 cm, localized) Yao (21) (UCSF criteria) Abbreviation: UCSF, University of California, San Francisco. *Four-year survival rate. TABLE 2. Living Donor Liver Transplantation for Hepatocellular Carcinoma Survival rate (%) Recurrence Study n r r (%) Todo (Japan, 24) 316 Met Milan criteria Did not meet Milan criteria Hwang (Korea, 25) 237 Met Milan criteria Did not meet Milan criteria Jonas (Germany, 27) 21 Met Milan criteria Did not meet Milan criteria Lo (Hong Kong, 27) 43 Within Milan or UCSF criteria A2ALL (USA, 27) All Abbreviation: UCSF, University of California, San Francisco. 75.2%, respectively, compared with a 5% 1-year survival for those who exceeded the criteria limits. Although patient survival was improved by adoption of the Milan criteria and/or the UCSF criteria, the high number of candidate dropouts due to the organ shortage remained an important problem. Thus, the United Network for Organ Sharing (UNOS) staging classification has been introduced under the Model for End- Stage Liver Disease (MELD) organ allocation policy. The classification includes T (no tumors), T1 (single tumor 1.9 cm), T2 (single tumor 5 cm, or 2-3 tumors 3 cm), T3 (single tumor 5 cm, or 2-3 tumors 3 cm), T4A ( 4 nodules of any size), and T4B (any stage with macroscopic vascular invasion). Patients with T2 tumor receive 21 MELD points. The outcome of the recipients with UNOS tumor stage T2 or less is equivalent to that obtained with recipients within the Milan criteria. LIVING DONOR LT Alternative alleviation of organ shortage is the use of liver grafts from living donors for transplantation. Living donor liver transplantation (LDLT), initially invented for pediatric recipients, has recently been applied to adult patients with benign liver diseases. In addition, it has extensively been performed in patients with HCC, particularly in countries where there are many patients with HCC but few deceased donor organ donations, like in Korea, Hong Kong, and Japan (Table 2). Of these, some centers strictly adhere to the Milan criteria for patient selection, whereas others make a case-by-case decision. The rationales behind the latter lie in evidence that LDLT offers theoretical survival benefit over DDLT by shortening the waiting time and lowering the dropout rate; that even in patients who exceed the Milan criteria and who are not eligible for DDLT, LDLT definitely provides an acceptable patient survival; and that LDLT is a family matter that weighs the risks and benefits for the recipient and donor, without jeopardizing the public resource of donated deceased donor organs. Previously, we performed a national survey of 316 adult patients with HCC undergoing LDLT at 49 centers
3 S5 TODO ET AL. LDLTx for HCC in Japan LDLTx Yes Milan Criteria? (Pathology) No 316 No Yes Recurrence? No Yes Figure 1. Living donor liver transplantation for hepatocellular carcinoma in Japan. during The results showed that LDLT demonstrated similar patient survival with the same recurrent risk factors as DDLT. In addition, nearly half the recipients who exceeded the Milan criteria survived for 3 years after LDLT. In the present study, by analyzing data from the preceding 316 patients and new recipients, we tried to determine new selection criteria to salvage HCC patients who are not eligible for DDLT because they exceed the Milan criteria, but who may receive survival benefit from LDLT alive died alive died alive died alive died Figure 2. Outcome of living donor liver transplantation for hepatocellular carcinoma in Japan. LIVING DONOR LT IN JAPAN Patients From October 1989 to December 25, a total of 653 patients with HCC received LDLT at 49 centers in Japan (Fig. 1). They were followed until the end of June 26, with a median follow-up period of 21.5 months (range, months). Median age was 56 years (range, 21-7 years). A total of 476 patients (72.9%) were male, and 177 (27.1%) were female. HCV infection was a leading cause of liver cirrhosis, occurring in 385 recipients (59%), vs. HBV for 199 (3%). Half the patients had advanced liver failure (Child-Pugh class C), whereas 3% were Child-Pugh class B and 1% were Child-Pugh class A. Patient Survival Of the 653 recipients, at time of last follow-up, 497 (76.1%) were alive without (n 451) or with (n 46) HCC recurrence; 156 (23.9%) had died of recurrent HCC (n 46) or for other reasons (n 11; Fig. 2). Actuarial patient survival was 82.6% at 1 year, 72.6% at 3 years, and 68.9% at 5 years; actuarial disease-free survival (DFS) was 77.4% at 1 year, 65.1% at 3 years, and 61.5% at 5 years (Fig. 3). By univariate analysis, pretransplantation serum levels of alfa-fetoprotein (AFP) and protein induced by vitamin K absence or antagonism factor II (PIVKA II), MELD score, and tumor characteristics of explanted livers (e.g., number and size of tumors, differentiation, and vascular invasion) were found to be important risk factors for patient survival. AFP and PIVKA II were found to be independent Figure 3. Patient survival, disease-free survival, and recurrence rate after living donor liver transplantation in Japan. risk factors for patient survival by multivariate analysis (Table 3). Patient survival of the patients who pathologically satisfied (n 337) and exceeded (n 316) the Milan criteria were 86.9% and 78.% at 1 year, 82.7% and 63.6% at 3 years, and 77.6% and 6% at 5 years, respectively (Fig. 4). HCC Recurrence Ninety-two recipients (14.1%) developed recurrence after LDLT. The cumulative recurrence rate was 9.2% at 1 year, 19.9% at 3 years, and 21.6% at 5 years. Tumor stage, age, AFP, PIVKA II, and pathological characteristics of tumors (e.g., number and size of tumors, distribution, vascular invasion, and differentiation) were closely associated with HCC recurrence by univariate analysis. By multivariate analysis, AFP, PIVKA II, vascular invasion, and number, distribution, and size of tumors were found to be independent risk factors for recurrence (Table 4). The recurrence rate of the patients who were within and beyond the Milan criteria were, respectively, 1.% and 17.7% at 1
4 LDLT FOR HCC IN JAPAN S51 TABLE 3. Mutivariate Analysis* of Risk Factors for Patient Survival Parameter P value Hazard ratio 95% confidence interval AFP (ng/ml) 1, , PIVKA II (mau/ml) 1, , Abbreviations: AFP, alfa-fetoprotein; PIVKA II, protein induced by vitamin K absence or antagonism factor II. *Cox proportional hazard model. LDLTx for HCC in Japan Milan Criteria (Pathology) Patient Survival Disease Free Survival Log Rank p<.1 year, 4.6% and 34.2% at 3 years, and 4.6% and 37.3% at 5 years. RISK FACTORS FOR HCC RECURRENCE AFP Levels Preoperative serum AFP levels were inversely correlated with patient survival: 83.8% at 1 year, 77.3% at 3 years, and 72.2% at 5 years when AFP was 2 ng/ml (n 473), and 64.9% at 1 year, 42.5% at 3 years, and 34.% at 5 years when AFP was 1, ng/ml (n 48). PIVKA II Levels Preoperative serum PIVKA II levels were also inversely correlated with patient survival; 96.2% at 1 year, 92.3% at 3 years, and 91.% at 5 years when PIVKA II was 1 mau/ml (n 386), and 71.9% at 1 year, 37.1% at 3 years, and 29.7% at 5 years when PIVKA II was 1, mau/ml (n 44). Vascular Invasion within (n=337) beyond (n=316) 1 LTx Survival of the patients with no vascular invasion, microscopic vascular invasion, or macroscopic vascular invasion (more than into the subsegmental portal Log Rank p<.1 Figure 4. Patient survival and disease-free survival by the Milan criteria in Japan. branches) were 72.1%, 63.4%, and 33.3% at 5 years, respectively. Of the 44 patients with tumors of UNOS stage 4B, 24 (54.5%) developed HCC recurrence, and 5-year DFS was only 2% (Fig. 5). Tumor Number Five-year DFS of the patients who had no tumor, 1, 2, 3, and 4 tumors were 1%, 95.9%, 88.4%, 81.2%, and 62.6%, respectively. Tumor Size Five-year DFS of patients with maximum tumor diameter of 2 cm, 5 cm, and 5 cm was 91.5%, 76.1% and 39.5%, respectively. Tumor Distribution Five-year DFS of the patients whose tumor or tumors were located at either lobe of the liver or in both lobes was 84.7% and 73.%, respectively. INFLUENCE OF PRETRANSPLANTATION TREATMENTS Of the 653 recipients, 466 (71.4%) received various adjuvant treatments, alone or in combination, before LDLT: transarterial chemoembolization (n 374), percutaneous ethanol injection (n 187), radiofrequency ablation or microwave coagulation therapy (n 92), and Hx (n 69). Neither pretransplantation treatments nor the type of modalities showed any influence on patient survival and recurrence rate, compared with those of the recipients who received no treatment (Fig. 6). Tumor Staging by Preoperative Imaging Studies Vs. Pathological Analysis of Explants Almost all of the criteria for patient selection have been made by pathological analysis of explanted livers. However, the decision to proceed to transplant or not depends on the tumor extension diagnosed by preoperative imaging studies, including computed tomography and/or magnetic resonance imaging. In this study, Milan criteria established by imaging studies were identical to pathological classifications in 78.3%, underesti-
5 S52 TODO ET AL. TABLE 4. Mutivariate Analysis* of Risk Factor for Hepatocellular Carcinoma Recurrence Parameter P value Hazard ratio 95% CI AFP (ng/ml) , 1, PIVKA II (mau/ml) , 1, Vascular invasion Vp Vp1 Number Distribution Unilobar 5. Bilobar 5. Abbreviations: AFP, alfa-fetoprotein; PIVKA II, protein induced by vitamin K absence or antagonism factor II. *Cox proportional hazard model LDLTx for HCC in Japan UNOS Tumor Stage (Pathology) Patient Survival Disease Free Survival Log Rank p<.1 LTx mated in 15.8%, and overestimated in 5.8%. No differences in patient survival, DFS, and recurrence rate were found between the 2 methods of staging. Fiveyear DFS of the recipients who met and exceeded the criteria by imaging diagnosis and pathological study was 91.6% and.5%, and 95.4% and 62.7%, respectively. Proposal of New Criteria Log Rank p<.1 Stage (n=14) Stage1 (n=77) Stage2 (n=246) Stage3 (n=45) Stage4a (n=227) Stage4b (n=42) Figure 5. Patient survival and disease-free survival for hepatocellular carcinoma by United Network for Organ Sharing tumor stage. We suggest that high serum AFP and PIVKA II levels before LDLT are closely associated with biological aggressiveness of HCC as expressed by macroscopic vascular invasion, larger tumor size, and more nodules. These relate to worse patient survival and worse DFS. AFP 2 ng/ml and PIVKA II 1 mau/ml were set as cutoff values (Fig. 7). We refer to these 2 values taken together as the A-P level. 4 2 LDLT for HCC in Japan Pre-Transplant Treatment Patient Survival Log Rank p=111 Recurrence 1 Treatment 1 No Treatment Criteria by Preoperative Imaging Study By preoperative imaging studies, 25 patients were found to have possible macroscopic vascular invasion, and 44 patients were diagnosed as not having HCC. Of the remaining 584 cases, 359 (61.5%) were within the Milan criteria, and 225 (38.5%) were beyond. Five-year DFS was 9% and 61.3%, respectively. When we exclude the 33 patients who lacked both AFP and PIVKA II levels, 343 satisfied the Milan criteria, and 28 were beyond them (Fig. 8). Five-year DFS of the patients who met the Milan criteria with lower (n 249) and higher (n 94) A-P level was 96.4% and 74.7%, respectively. In the patients who exceeded the criteria, 5-year DFS was 78.7% if A-P levels were below the Milan criteria (n 12); it was 39.9% when they were above the criteria (n 16). Thus, nearly half of the recipients who exceeded the Milan criteria but who had lower A-P levels Log Rank p=.7284 Figure 6. Patient survival and recurrence rate with or without preoperative treatment for hepatocellular carcinoma in Japan.
6 LDLT FOR HCC IN JAPAN S53 AP levels Pathology T Within 1. (325) Beyond (272) (28) Within, AP-Yes (96) Within, AP-No Beyond, AP-Yes (124).. <1 <2 <1 >1. T4b. Beyond, AP-No (131) Figure 7. A-P (alfa-fetoprotein <2 ng/ml and protein induced by vitamin K absence or antagonism factor II <1 mau/ml) levels. Image Figure 9. Milan criteria and A-P (alfa-fetoprotein <2 ng/ml and protein induced by vitamin K absence or antagonism factor II <1 mau/ml) levels (pathological diagnosis). the A-P levels were found to survive as long as those who met the criteria. 1. T. T4b Within (343) Beyond (28) were found to achieve similar DFS as those who satisfied the Milan criteria. Criteria by Postoperative Pathological Study Sixteen patients had HCC lesions that were totally necrotic as a result of preoperative treatment, and 44 patients had extensive vascular invasion. When we exclude these patients and the 38 patients without data for both these measurements, the 5-year DFS of those who met (n 325) and exceeded (n 272) the criteria were 95.3% and 66.4%, respectively (Fig. 9). When the A-P levels were below the criteria, the 5-year DFS of the patients who were within and exceeded the criteria were 99.5% (n 28) and 84.3% (n 124), although those with higher A-P levels had a 5-year DFS of 85.% (n 96) and 45.% (n 131), respectively. As with the imaging analysis, half the patients who exceeded the criteria but who satisfied 1.. (249) Within, AP-Yes (12) Beyond, AP-Yes Within, AP-No (94) Beyond, AP-No (16) Figure 8. Milan criteria and A-P (alfa-fetoprotein <2 ng/ml and protein induced by vitamin K absence or antagonism factor II <1 mau/ml) levels (imaging diagnoses). SUMMARY AND CONCLUSION The Milan criteria have been accepted as a standard for selection of HCC patients in DDLT worldwide. In the present study, the results of 653 Japanese recipients demonstrate that it is also applicable to LDLT. Although the criteria were originally created by pathological studies of explanted livers, criteria determined by preoperative imaging diagnosis showed the same prognostic power. The criteria were found to be able to predict the outcome of patients who underwent various attempts at pretransplantation tumor control, suggesting the usefulness of downstaging tumors to limit extension within the criteria. Thus, the reliability of the criteria for outcome estimation after LDLT was confirmed with a much larger patient population with a much longer follow-up than the previous study. However, the present study, as well as other DDLT studies, demonstrated that nearly half of the recipients who exceeded the criteria and would be removed from the waiting list survived free of disease for 5 years. Several efforts have been attempted to extend the indication to salvage these recipients, such as the UCSF criteria and the Barcelona Clinic Liver Cancer staging criteria, by using pathological tumor characteristics. In this study, we introduced A-P levels: AFP 2 ng/ml and PIVKA II 1 mau/ml. Both molecules have been used as serological markers of HCC, and they have been found to correlate with their biological behaviors. By using both the Milan criteria and the A-P levels, our study could differentiate the outcome of the recipients who were beyond the criteria into 2 groups: low A-P level patients (5%) with satisfactory survival without recurrence, and the other high A-P level patients (5%) with high recurrence rates. Although more detailed analyses are still in progress, our results indicate that molecular information reflecting HCC biology
7 S54 TODO ET AL. is needed to determine recipient outcome after both DDLT and LDLT. BIBLIOGRAPHY 1. Cillo U, Vitale A, Grigoletto F, Farinati F, Brolese A, Zanus G, et al. Prospective validation of the Barcelona Clinic Liver Cancer staging system. J Hepatol 26;44: El-Serag HB. Hepatocellular carcinoma: recent trends in the United States. Gastroenterology 24;127(5 Suppl 1): S27-S Fisher RA, Kulik LM, Freise CE, Lok AS, Shearon TH, Brown RS Jr, et al, for the A2ALL Study Group. Hepatocellular carcinoma recurrence and death following living and deceased donor liver transplantation. Am J Transplant 27;7: Iwatsuki S, Dvorchik I, Marsh JW, Madariaga JR, Carr B, Fung JJ, et al. Liver transplantation for hepatocellular carcinoma: a proposal of a prognostic scoring system. J Am Coll Surg 2;191: Iwatsuki S, Starzl TE, Sheahan DG, Yokoyama I, Demetris AJ, Todo S, et al. Hepatic resection versus transplantation for hepatocellular carcinoma. Ann Surg 1991;214: Jonas S, Bechstein WO, Steinmüller T, Herrmann M, Radke C, Berg T, et al. Vascular invasion and histopathologic grading determine outcome after liver transplantation for hepatocellular carcinoma in cirrhosis. Hepatology 21;33: Kaihara S, Kiuchi T, Ueda M, Oike F, Fujimoto Y, Ogawa K, et al. Living-donor transplantation for hepatocellular carcinoma. Transplantation 23;75:S37-S4. 8. Lo CM, Fan ST, Liu CL, Chan SC, Wong J. The role and limitation of living donor liver transplantation for hepatocellular carcinoma. Liver Transpl 24;1: Mazzaferro V, Regalia E, Doci R, Andreola S, Pulvirenti A, Bozzetti F, et al. Liver transplantation for the treatment of small hepatocellular carcinoma in patients with cirrhosis. N Engl J Med 1996;334: Otto G, Herber S, Heise M, Lohse AW, Mönch C, Bittinger F, et al. Response to transarterial chemoembolization as a biologic selection criterion for liver transplantation in hepatocellular carcinoma. Liver Transpl 26;12: Soejima Y, Taketomi A, Yoshizumi T, Uchiyama H, Aishima S, Terashi T, et al. Extended indication for living donor liver transplantation in patients with hepatocellular carcinoma. Transplantation 27;83: Starzl TE, Putnam CW. Candidacy. In: Starzl TE, Putnam CW, eds. Experience in Hepatic Transplantation. Philadelphia, PA: WB Saunders; 1969: Takada Y, Ueda M, Ito T, Sakamoto S, Haga H, Maetani Y, et al. Living donor liver transplantation as a second line therapeutic strategy for patients with hepatocellular carcinoma. Liver Transpl 26;12: Todo S, Furukawa H, on behalf of the Japanese Study Group on Organ Transplantation. Living donor liver transplantation for adult patients with hepatocellular carcinoma experience in Japan. Ann Surg 24;24: Yao FY, Ferrell L, Bass NM, Watson JJ, Bacchetti P, Venook A, et al. Liver transplantation for hepatocellular carcinoma: expansion of the tumor size limits does not adversely impact survival. Hepatology 21;33: Yao FY, Hirose R, LaBerge JM, Davern TJ 3rd, Bass NM, Kerlan RK Jr, et al. A prospective study of downstaging of hepatocellular carcinoma prior to liver transplantation. Liver Transpl 25;11:
Selection of patients of hepatocellular carcinoma beyond the Milan criteria for liver transplantation
Title Selection of patients of hepatocellular carcinoma beyond the Milan criteria for liver transplantation Author(s) Chan, SC; Fan, ST Citation Hepatobiliary Surgery and Nutrition, 2013, v. 2 n. 2, p.
More informationHPB ORIGINAL ARTICLE. Abstract. Keywords. Correspondence. Introduction
DOI:1111/j.1477-2574.2009.00022.x HPB ORIGINAL ARTICLE Poorer survival in patients whose explanted hepatocellular carcinoma (HCC) exceeds Milan or UCSF Criteria. An analysis of liver transplantation in
More informationManagement of HepatoCellular Carcinoma
9th Symposium GIC St Louis - 2010 Management of HepatoCellular Carcinoma Overview Pierre A. Clavien, MD, PhD Department of Surgery University Hospital Zurich Zurich, Switzerland Hepatocellular carcinoma
More informationLiver Transplantation for Hepatocellular Carcinoma: Validation of the UCSF-Expanded Criteria Based on Preoperative Imaging
American Journal of Transplantation 2007; 7: 2587 2596 Blackwell Munksgaard C 2007 The Authors Journal compilation C 2007 The American Society of Transplantation and the American Society of Transplant
More informationLiving Donor Liver Transplantation for Hepatocellular Carcinoma: It Is All about Donors?
Original Article Living Donor Liver Transplantation for Hepatocellular Carcinoma: It Is All about Donors? R. F. Saidi 1 *, Y. Li 2, S. A. Shah 2, N. Jabbour 2 1 Division of Organ Transplantation, Department
More informationDespite recent advances in the care of patients with
Liver Transplantation for Hepatocellular Carcinoma: Lessons from the First Year Under the Model of End- Stage Liver Disease (MELD) Organ Allocation Policy Francis Y. Yao, 1,2 Nathan M. Bass, 1 Nancy L.
More informationDepartment of Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea
ORIGINAL ARTICLE pissn -575 eissn -79 https://doi.org/1.17/astr.1.95..111 Annals of Surgical Treatment and Research Clinical usefulness of transarterial chemoembolization response prior to liver transplantation
More informationSurveillance for Hepatocellular Carcinoma
Surveillance for Hepatocellular Carcinoma Marion G. Peters, MD John V. Carbone, MD, Endowed Chair Professor of Medicine Chief of Hepatology Research University of California San Francisco Recorded on April
More informationLiver transplantation: Hepatocellular carcinoma
Liver transplantation: Hepatocellular carcinoma Alejandro Forner BCLC Group. Liver Unit. Hospital Clínic. University of Barcelona 18 de marzo 2015 3r Curso Práctico de Transplante de Órganos Sólidos Barcelona
More informationSurvival advantage of primary liver transplantation for hepatocellular carcinoma within the up-to-7 criteria with microvascular invasion
Title Author(s) Survival advantage of primary liver transplantation for hepatocellular carcinoma within the up-to-7 criteria with microvascular invasion Chan, SC; Fan, ST; Chok, KSH; Cheung, TT; Chan,
More informationShould the Liver Transplant Criteria for Hepatocellular Carcinoma Be Different for Deceased Donation and Living Donation?
LIVER TRANSPLANTATION 17:S133-S138, 2011 SUPPLEMENT Should the Liver Transplant Criteria for Hepatocellular Carcinoma Be Different for Deceased Donation and Living Donation? David Grant, 1,2,5 Robert A.
More informationHCC RADIOLOGIC DIAGNOSIS
UCSF Transplant 2010 THE BEFORE AND AFTER HEPATOCELLULAR CARCINOMA MANAGEMENT Francis Yao, M.D. Professor of Clinical Medicine and Surgery Medical Director, Liver Transplantation University of California,
More informationHepatocellular Carcinoma Recurrence and Death Following Living and Deceased Donor Liver Transplantation
American Journal of Transplantation 2007; 7: 1601 1608 Blackwell Munksgaard C 2007 The Authors Journal compilation C 2007 The American Society of Transplantation and the American Society of Transplant
More informationLiving donor liver transplantation for patients with hepatocellular carcinoma in Japan
Sugawara et al. Hepatoma Res 2018;4:33 DOI: 10.20517/2394-5079.2018.69 Hepatoma Research Review Open Access Living donor liver transplantation for patients with hepatocellular carcinoma in Japan Yasuhiko
More informationLiving donor liver transplantation for hepatocellular carcinoma in Seoul National University
Original Article on Liver Transplantation for Hepatocellular Carcinoma Living donor liver transplantation for hepatocellular carcinoma in Seoul National University Suk Kyun Hong, Kwang-Woong Lee, Hyo-Sin
More informationLiving vs. deceased-donor liver transplantation for patients with hepatocellular carcinoma
Review Article Living vs. deceased-donor liver transplantation for patients with hepatocellular carcinoma Kohei Ogawa, Yasutsugu Takada Department of HB and Breast Surgery, Ehime University, Ehime, Japan
More informationHepatocellular Carcinoma: Transplantation, Resection or Ablation?
Hepatocellular Carcinoma: Transplantation, Resection or Ablation? Roberto Gedaly MD Chief, Abdominal Transplantation Transplant Service Line University of Kentucky Nothing to disclose Disclosure Objective
More informationLiving Donor Liver Transplantation Versus Deceased Donor Liver Transplantation for Hepatocellular Carcinoma: Comparable Survival and Recurrence
LIVER TRANSPLANTATION 18:315-322, 2012 ORIGINAL ARTICLE Living Donor Liver Transplantation Versus Deceased Donor Liver Transplantation for Hepatocellular Carcinoma: Comparable Survival and Recurrence Lakhbir
More informationLiving donor liver transplantation for hepatocellular carcinoma at the University of Tokyo Hospital
Original Article on Liver Transplantation for Hepatocellular Carcinoma Living donor liver transplantation for hepatocellular carcinoma at the University of Tokyo Hospital Junichi Togashi, Nobuhisa Akamastu,
More informationShould we expand the criteria for liver transplantation for hepatocellular carcinoma Yes, of course!
Forum on Liver Transplantation 569 Should we expand the criteria for liver transplantation for hepatocellular carcinoma Yes, of course! Christoph Erich Broelsch*, Andrea Frilling, Massimo Malago Department
More informationReconsidering Liver Transplantation for HCC in a Era of Organ shortage
Reconsidering Liver Transplantation for HCC in a Era of Organ shortage Professor Didier Samuel Centre Hépatobiliaire Inserm-Paris Sud Research Unit 1193 Departement Hospitalo Universitaire Hepatinov Hôpital
More informationHepatocellular Carcinoma. Markus Heim Basel
Hepatocellular Carcinoma Markus Heim Basel Outline 1. Epidemiology 2. Surveillance 3. (Diagnosis) 4. Staging 5. Treatment Epidemiology of HCC Worldwide, liver cancer is the sixth most common cancer (749
More informationDepartment of Surgery, The University of Hong Kong Medical Centre, Queen Mary Hospital, Hong Kong, China
The Oncologist Hepatobiliary Liver Transplantation for Hepatocellular Carcinoma in Asia VANESSA DE VILLA,CHUNG MAU LO Department of Surgery, The University of Hong Kong Medical Centre, Queen Mary Hospital,
More informationTumor incidence varies significantly, depending on geographical location.
Hepatocellular carcinoma is the 5 th most common malignancy worldwide with male-to-female ratio 5:1 in Asia 2:1 in the United States Tumor incidence varies significantly, depending on geographical location.
More informationTherapeutic options for hepatocellular carcinoma
GASTROENTEROLOGY 2005;128:1752 1764 Liver Transplantation for Hepatocellular Carcinoma ALEX S. BEFELER, PAUL H. HAYASHI, and ADRIAN M. DI BISCEGLIE Saint Louis University Liver Center, Saint Louis University,
More information9/10/2018. Liver Transplant for Hepatocellular Carcinoma (HCC): What is New? DISCLOSURES
UCSF Transplant 2018: Pioneering Advances in Transplantation DISCLOSURES Liver Transplant for Hepatocellular Carcinoma (HCC): What is New? I have no relevant commercial interests or relationships to report
More informationHepatocellular Carcinoma (HCC): Who Should be Screened and How Do We Treat? Tom Vorpahl MSN, RN, ACNP-BC
Hepatocellular Carcinoma (HCC): Who Should be Screened and How Do We Treat? Tom Vorpahl MSN, RN, ACNP-BC Objectives Identify patient risk factors for hepatocellular carcinoma (HCC) Describe strategies
More informationLiver Transplantation for Hepatocellular Carcinoma
Annals of Surgical Oncology 15(4):1001 1007 DOI: 10.1245/s10434-007-9559-5 Liver Transplantation for Hepatocellular Carcinoma Vincenzo Mazzaferro, MD, 1 Yun Shin Chun, MD, 2 Ronnie T. P. Poon, MS, PhD,
More informationOptimizing Patient Selection, Organ Allocation, and Outcomes in Liver Transplant (LT) Candidates with Hepatocellular Carcinoma (HCC)
XXVI SETH Congress- 30 November 2017 Optimizing Patient Selection, Organ Allocation, and Outcomes in Liver Transplant (LT) Candidates with Hepatocellular Carcinoma (HCC) Neil Mehta, MD University of California,
More informationSince liver transplantation (LT) was first proposed. Liver Transplantation for Hepatocellular Carcinoma: Further Considerations on Selection Criteria
Liver Transplantation for Hepatocellular Carcinoma: Further Considerations on Selection Criteria Matteo Ravaioli, 1 Giorgio Ercolani, 1 Matteo Cescon, 1 Gaetano Vetrone, 1 Claudio Voci, 2 * Walter Franco
More informationPrognosis of Hepatocellular Carcinoma after Liver Transplantation: Comparative Analysis with Partial Hepatectomy
Journal of Pathology and Translational Medicine 2017; 51: 79-86 ORIGINAL ARTICLE Prognosis of Hepatocellular Carcinoma after Liver Transplantation: Comparative Analysis with Partial Hepatectomy Kyuho Lee
More informationLiver Transplantation in Hepatocellular Carcinoma
Trends in Transplant. 2010;4:51-7 José Fuster, et al.: Liver Transplantation in Hepatocellular Carcinoma Liver Transplantation in Hepatocellular Carcinoma José Fuster, Constantino Fondevila, Santiago Sánchez,
More informationCirrhotic patients with solitary hepatocellular carcinoma
ORIGINAL ARTICLES Survival of Cirrhotic Patients With Early Hepatocellular Carcinoma Treated by Percutaneous Ethanol Injection or Liver Transplantation Angelo Andriulli, 1 Ilario de Sio, 2 Luigi Solmi,
More informationCelsion Symposium New Paradigms in HCC Staging: HKLC vs. BCLC Staging
Celsion Symposium New Paradigms in HCC Staging: HKLC vs. BCLC Staging Ronnie T.P. Poon, MBBS, MS, PhD Chair Professor of Hepatobiliary and Pancreatic Surgery Chief of Hepatobiliary and Pancreatic Surgery
More informationRole of positron emission tomography/computed tomography in living donor liver transplantation for hepatocellular carcinoma
Review Article on Liver Transplantation for Hepatocellular Carcinoma Role of positron emission tomography/computed tomography in living donor liver transplantation for hepatocellular carcinoma Seung Duk
More informationLiver Transplantation for HCC Which Criteria?
Liver Transplantation for HCC Which Criteria? Jacques Belghiti - François Durand Claire Francoz Hepato-Biliary-Pancreatic Liver Surgery and Liver Transplantation Unit Hôpital Beaujon (AP-HP), Clichy -
More informationSummary of Candidate Selection and Expanded Criteria for Liver Transplantation for Hepatocellular Carcinoma: A Review and Consensus Statement
LIVER TRANSPLANTATION 17:S81-S89, 2011 SUPPLEMENT Summary of Candidate Selection and Expanded Criteria for Liver Transplantation for Hepatocellular Carcinoma: A Review and Consensus Statement K. Raj Prasad,
More informationLiver transplantation for hepatocellular carcinoma with live donors or extended criteria donors: a propensity score-matched comparison
ORIGINAL ARTICLE Annals of Gastroenterology (2018) 31, 722-727 Liver transplantation for hepatocellular carcinoma with live donors or extended criteria donors: a propensity score-matched comparison Georgios
More informationWaitlist Priority for Hepatocellular Carcinoma Beyond Milan Criteria: A Potentially Appropriate Decision Without a Structured Approach
American Journal of Transplantation 2014; 14: 79 87 Wiley Periodicals Inc. C Copyright 2013 The American Society of Transplantation and the American Society of Transplant Surgeons doi: 10.1111/ajt.12530
More informationLiver resection for HCC
8 th LIVER INTEREST GROUP Annual Meeting Cape Town 2017 Liver resection for HCC Jose Ramos University of the Witwatersrand Donald Gordon Medical Centre The liver is almost unique in that treatment of the
More informationPATIENTS AND METHODS. Data Source
LIVER TRANSPLANTATION 20:1045 1056, 2014 ORIGINAL ARTICLE Waiting Time Predicts Survival After Liver Transplantation for Hepatocellular Carcinoma: A Cohort Study Using the United Network for Organ Sharing
More informationOnce considered a relative contraindication to
Downstaging of Hepatocellular Cancer Before Liver Transplant: Long-Term Outcome Compared to Tumors Within Milan Criteria Francis Y. Yao, 1,2 Neil Mehta, 1 Jennifer Flemming, 1 Jennifer Dodge, 2 Bilal Hameed,
More informationHepatocellular Carcinoma in HIV-infected Patients A Growing Complication of Coinfection with HCV or HBV Mon, 31 May 2010
Bronx VA Medical Center Mount Sinai School of Medicine Hepatocellular Carcinoma in HIV-infected Patients A Growing Complication of Coinfection with HCV or HBV Mon, 31 May 2010 Norbert Bräu, MD, MBA Associate
More informationMacrovascular Invasion Is Not an Absolute Contraindication for Living Donor Liver Transplantation
ORIGINAL ARTICLE LEE ET AL. Macrovascular Invasion Is Not an Absolute Contraindication for Living Donor Liver Transplantation Kwang-Woong Lee, 1 Suk-Won Suh, 1 YoungRok Choi, 1 Jaehong Jeong, 1 Nam-Joon
More informationHCC: Is it an oncological disease? - No
June 13-15, 2013 Berlin, Germany Prof. Oren Shibolet Head of the Liver Unit, Department of Gastroenterology Tel-Aviv Sourasky Medical Center and Tel-Aviv University HCC: Is it an oncological disease? -
More informationOutcomes of Living and Deceased Donor Liver Transplant Recipients With Hepatocellular Carcinoma: Results of the A2ALL Cohort
American Journal of Transplantation 2012; 12: 2997 3007 Wiley Periodicals Inc. C Copyright 2012 The American Society of Transplantation and the American Society of Transplant Surgeons doi: 10.1111/j.1600-6143.2012.04272.x
More informationHepatocellular carcinoma (HCC) is the third
Intention-to-Treat Analysis of Liver Transplantation for Hepatocellular Carcinoma: Living Versus Deceased Donor Transplantation Prashant Bhangui, 1 Eric Vibert, 1,2,4 Pietro Majno, 5 Chady Salloum, 1 Paola
More informationLiver Transplant Program, Chang Gung Memorial Hospital, Taoyuan 33378, Taipei, China
Original Article Salvage transplantation for post-resection recurrence in hepatocellular carcinoma associated with hepatitis C virus etiology: a feasible strategy? Bhavin Bhupendra Vasavada 1, Chao-Long
More informationReview Article Liver Transplantation for Hepatocellular Carcinoma beyond Milan Criteria: Multidisciplinary Approach to Improve Outcome
ISRN Hepatology, Article ID 706945, 25 pages http://dx.doi.org/10.1155/2014/706945 Review Article Liver Transplantation for Hepatocellular Carcinoma beyond Milan Criteria: Multidisciplinary Approach to
More informationLiver transplantation (LT) is a widely accepted
Original Article / Transplantation Hepatobiliary & Pancreatic Diseases International Comparison of hepatitis B prophylactic outcomes in living donor liver transplantation recipients who meet the Milan
More informationTumor Response to Transcatheter Arterial Chemoembolization in Recurrent Hepatocellular Carcinoma after Living Donor Liver Transplantation
Tumor Response to Transcatheter Arterial Chemoembolization in Recurrent Hepatocellular Carcinoma after Living Donor Liver Transplantation Heung-Kyu Ko, MD 1 Gi-Young Ko, MD 2 Hyun Ki Yoon, MD 2 Kyu-Bo
More informationLiver Cancer: Diagnosis and Treatment Options
Liver Cancer: Diagnosis and Treatment Options Fred Poordad, MD Chief, Hepatology University Transplant Center Professor of Medicine UT Health, San Antonio VP, Academic and Clinical Affairs, Texas Liver
More informationMultimodal therapy for hepatocellular carcinoma: A complementary approach to liver transplantation
ORIGINAL ARTICLE Multimodal therapy for hepatocellular carcinoma: a complementary approach to liver transplantation., 2010; 9 (1): 23-32 January-March, Vol. 9 No.1, 2010: 23-32 23 ABSTRACT Multimodal therapy
More informationWHAT IS THE BEST APPROACH FOR TRANS-ARTERIAL THERAPY IN HCC?
WHAT IS THE BEST APPROACH FOR TRANS-ARTERIAL THERAPY IN HCC? Dr. Alexander Kim Chief, Vascular and Interventional Radiology, Medstar Georgetown University Hospital, USA DISCLAIMER Please note: The views
More informationLiving donor liver transplantation for hepatocellular carcinoma achieves better outcomes
Review Article on Liver Transplantation for Hepatocellular Carcinoma Living donor liver transplantation for hepatocellular carcinoma achieves better outcomes Chih-Che Lin, Chao-Long Chen Liver Transplantation
More informationLiver transplanta-on with extented Milan criteria
Liver transplanta-on with extented Milan criteria Pr Olivier Detry Dpt of Abdominal Surgery & Transplanta-on CHU Liege, University of Liege Liver transplanta-on for HCC: do size & number really maher??
More informationAdult-to-adult living donor liver transplantation Triumphs and challenges
Falk Symposium No. 163 on Chronic Inflammation of Liver and Gut Adult-to-adult living donor liver transplantation Triumphs and challenges ST Fan, MS, MD, PhD, DSc Professor Sun CY Chair of Hepatobiliary
More informationRadiofrequency Ablation of Primary or Metastatic Liver Tumors
Radiofrequency Ablation of Primary or Metastatic Liver Tumors Policy Number: 7.01.91 Last Review: 9/2018 Origination: 2/1996 Next Review: 9/2019 Policy Blue Cross and Blue Shield of Kansas City (Blue KC)
More informationHistorically, hepatocellular carcinoma (HCC)
Delayed Hepatocellular Carcinoma Model for End-Stage Liver Disease Exception Score Improves Disparity in Access to Liver Transplant in the United States Julie K. Heimbach, 1 Ryutaro Hirose, 2 Peter G.
More informationHepatocellular carcinoma
Hepatocellular carcinoma Mary Ann Y. Huang, M.D., M.S., FAASLD Transplant hepatologist Peak Gastroenterology Associates Porter Adventist Hospital Denver, Colorado Background - Worldwide Hepatocellular
More informationIn early but unresectable hepatocellular carcinoma (HCC),
Journal of Nuclear Medicine, published on April 16, 2009 as doi:10.2967/jnumed.108.060574 Prediction of Tumor Recurrence by F-FDG PET in Liver Transplantation for Hepatocellular Carcinoma Jeong Won Lee
More informationHepatocellular carcinoma (HCC) is the third
Original Article / Transplantation Outcomes of loco-regional therapy for down-staging of hepatocellular carcinoma prior to liver transplantation Xian-Jie Shi, Xin Jin, Mao-Qiang Wang, Li-Xin Wei, Hui-Yi
More informationLiver Cancer: Epidemiology and Health Disparities. Andrea Goldstein NP, MS, MPH Scientific Director Onyx Pharmaceuticals
Liver Cancer: Epidemiology and Health Disparities Andrea Goldstein NP, MS, MPH Scientific Director Onyx Pharmaceuticals 1. Bosch FX, et al. Gastroenterology. 2004;127(5 suppl 1):S5-S16. 2. American Cancer
More informationTREATMENT FOR HCC AND CHOLANGIOCARCINOMA. Shawn Pelletier, MD
TREATMENT FOR HCC AND CHOLANGIOCARCINOMA Shawn Pelletier, MD Treatment for HCC Treatment strategies Curative first line therapy Thermal ablation vs Resection vs Transplant Other first line therapies TACE
More informationHepatocellular Carcinoma: Diagnosis and Management
Hepatocellular Carcinoma: Diagnosis and Management Nizar A. Mukhtar, MD Co-director, SMC Liver Tumor Board April 30, 2016 1 Objectives Review screening/surveillance guidelines Discuss diagnostic algorithm
More informationTotal Tumor Volume and Alpha Fetoprotein for selection of transplant candidates. with hepatocellular carcinoma: a prospective validation
Total Tumor Volume and Alpha Fetoprotein for selection of transplant candidates with hepatocellular carcinoma: a prospective validation Christian Toso 1, Glenda Meeberg 2, Roberto Hernandez-Alejandro 3,
More informationAlpha-Fetoprotein-L3 for Detection of Hepatocellular (Liver) Cancer. Original Policy Date
MP 2.04.35 Alpha-Fetoprotein-L3 for Detection of Hepatocellular (Liver) Cancer Medical Policy Section Medicine Issue 12:2013 Original Policy Date 12:2013 Last Review Status/Date Reviewed with literature
More informationPediatric Liver Tumors and Transplantation. Northwest Regional Pediatric Live Disease Symposium, Seattle WA, April 12, 2008
Pediatric Liver Tumors and Transplantation Northwest Regional Pediatric Live Disease Symposium, Seattle WA, April 12, 2008 Liver transplantation for primary liver tumours in children WHEN? - patient selection
More informationPaul Martin MD FACG. University of Miami
Paul Martin MD FACG University of Miami 1 Liver cirrhosis of any cause Chronic C o c hepatitis epat t s B Risk increases with Male gender Age Diabetes Smoking ~5% increase in HCV-related HCC between 1991-28
More informationHepatocellular Carcinoma Recurrence After Liver Transplantation: an Analysis of Risk Factors and Incidence from Oregon Health & Science University
Portland State University PDXScholar University Honors Theses University Honors College 2016 Hepatocellular Carcinoma Recurrence After Liver Transplantation: an Analysis of Risk Factors and Incidence from
More informationSalvage Liver Transplantation for Recurrent Hepatocellular Carcinoma after Liver Resection: Retrospective Study of the Milan and Hangzhou Criteria
Salvage Liver Transplantation for Recurrent Hepatocellular Carcinoma after Liver Resection: Retrospective Study of the Milan and Hangzhou Criteria Zhenhua Hu 1,2,3, Jie Zhou 1,2,3, Zhiwei Li 1,2,3, Jie
More informationLiver Transplant. Description
Subject: Liver Transplant Page: 1 of 27 Last Review Status/Date: March 2014 Liver Transplant Description Background Recipients Liver transplantation is now routinely performed as a treatment of last resort
More informationLiver Transplantation for Hepatocellular Carcinoma: A Proposal of a Prognostic Scoring System
Liver Transplantation for Hepatocellular Carcinoma: A Proposal of a Prognostic Scoring System Shunzaburo Iwatsuki, MD, PhD, FACS, Igor Dvorchik, PhD, J Wallis Marsh, MD, FACS, Juan R Madariaga, MD, FACS,
More informationdoi: /hepr Response Evaluation Criteria in Cancer of the Liver (RECICL) (2015 Revised version)
bs_bs_banner Hepatology Research 2016; 46: 3 9 doi: 10.1111/hepr.12542 Special Report Response Evaluation Criteria in Cancer of the Liver (RECICL) (2015 Revised version) Masatoshi Kudo, Kazuomi Ueshima,
More informationTreatment of Hepatocellular Carcinoma. Andrew J. Muir, MD MHS Division of Gastroenterology Duke University Medical Center
Treatment of Hepatocellular Carcinoma Andrew J. Muir, MD MHS Division of Gastroenterology Duke University Medical Center Epidemiology of HCC: world The 5 th most common cancer worldwide > 500, 000 new
More informationTakahito Nakagawa, MD, Toshiya Kamiyama, MD, Kazuaki Nakanishi, MD, Hideki Yokoo, MD, Hirofumi Kamachi, MD, Michiaki Matsushita, MD, Satoru Todo, MD
Pulmonary for metastases from hepatocellular carcinoma: Factors influencing prognosis Takahito Nakagawa, MD, Toshiya Kamiyama, MD, Kazuaki Nakanishi, MD, Hideki Yokoo, MD, Hirofumi Kamachi, MD, Michiaki
More informationCurrent Concepts in Hepatocellular Carcinoma and Liver Transplantation: A Review and 2014 Update
REVIEW ARTICLE Current Concepts in Hepatocellular Carcinoma and Liver Transplantation: 10.5005/jp-journals-10018-1123 A Review and 2014 Update Current Concepts in Hepatocellular Carcinoma and Liver Transplantation:
More informationExpansion of the Milan criteria without any sacrifice: combination of the Hangzhou criteria with the pre-transplant platelet-tolymphocyte
Xia et al. BMC Cancer (2017) 17:14 DOI 10.1186/s12885-016-3028-0 RESEARCH ARTICLE Open Access Expansion of the Milan criteria without any sacrifice: combination of the Hangzhou criteria with the pre-transplant
More informationHCC surgical approach: resection and transplantation indications and outcome
SAMO, Friday 15th April 2011 Workshop on Primary liver tumors HCC surgical approach: resection and transplantation indications and outcome Gilles Mentha University Hospital of Geneva Hepatocellular Carcinoma
More informationNHS BLOOD AND TRANSPLANT ORGAN DONATION AND TRANSPLANTATION DIRECTORATE LIVER ADVISORY GROUP UPDATE ON THE HCC DOWN-STAGING SERVICE EVALUATION
NHS BLOOD AND TRANSPLANT ORGAN DONATION AND TRANSPLANTATION DIRECTORATE LIVER ADVISORY GROUP UPDATE ON THE HCC DOWN-STAGING SERVICE EVALUATION 1. A service development evaluation to transplant down-staged
More informationABSTRACT INTRODUCTION
/, 2017, Vol. 8, (No. 29), pp: 47555-47564 Comparison of treatment outcome between living donor liver transplantation and sorafenib for patients with hepatocellular carcinoma beyond the Milan criteria
More information6/16/2016. Treating Hepatocellular Carcinoma: Deciphering the Clinical Data. Liver Regeneration. Liver Regeneration
Treating : Deciphering the Clinical Data Derek DuBay, MD Associate Professor of Surgery Director of Liver Transplant Liver Transplant and Hepatobiliary Surgery UAB Department of Surgery Liver Regeneration
More informationIS THERE A DIFFERENCE IN LIVER CANCER RATES IN PATIENTS WHO RECEIVE TREATMENT FOR HEPATITIS?
IS THERE A DIFFERENCE IN LIVER CANCER RATES IN PATIENTS WHO RECEIVE TREATMENT FOR HEPATITIS? Dr. Sammy Saab David Geffen School of Medicine, Los Angeles, USA April 2018 DISCLAIMER Please note: The views
More informationHepatobiliary Malignancies Retrospective Study at Truman Medical Center
Hepatobiliary Malignancies 206-207 Retrospective Study at Truman Medical Center Brandon Weckbaugh MD, Prarthana Patel & Sheshadri Madhusudhana MD Introduction: Hepatobiliary malignancies are cancers which
More informationPrediction of Progression-Free Survival in Patients Presenting with Hepatocellular Carcinoma Within the Milan Criteria
LIVER TRANSPLANTATION 16:503-512, 2010 ORIGINAL ARTICLE Prediction of Progression-Free Survival in Patients Presenting with Hepatocellular Carcinoma Within the Milan Criteria Massimo De Giorgio, 1 * Stefano
More informationWorldwide Causes of HCC
Approach to HCV Treatment in Patients with HCC JORGE L. HERRERA, MD, MACG UNIVERSITY OF SOUTH ALABAMA COLLEGE OF MEDICINE Worldwide Causes of HCC 60% 50% 40% 54% 30% 20% 10% 31% 15% 0% Hepatitis B Hepatitis
More information9th Paris Hepatitis Conference
9th Paris Hepatitis Conference Paris, 12 January 2016 Treatment of hepatocellular carcinoma: beyond international guidelines Massimo Colombo Chairman Department of Liver, Kidney, Lung and Bone Marrow Units
More information3/22/2017. I will be discussing off label/investigational use of tivantinib for hepatocellular carcinoma.
Grant/Research Support - AbbVie, Conatus, Hologic, Intercept, Genfit, Gilead, Mallinckrodt, Merck, Salix, Shire, Vital Therapies Consultant AbbVie, Gilead, Merck Member, Scientific Advisory Board Vital
More informationRESEARCH ARTICLE. Validation of The Hong Kong Liver Cancer Staging System in Patients with Hepatocellular Carcinoma after Curative Intent Treatment
DOI:10.22034/APJCP.2017.18.6.1697 RESEARCH ARTICLE Validation of The Hong Kong Liver Cancer Staging System in Patients with Hepatocellular Carcinoma after Curative Intent Treatment Alan Chuncharunee 1,
More informationMANAGEMENT OF COLORECTAL METASTASES. Robert Warren, MD. The Postgraduate Course in General Surgery March 22, /22/2011
MANAGEMENT OF COLORECTAL METASTASES Robert Warren, MD The Postgraduate Course in General Surgery March 22, 2011 Local Systemic LIVER TUMORS:THERAPEUTIC OPTIONS Hepatoma Cholangio. Neuroendo. Colorectal
More informationHepatocellular Carcinoma (HCC)
Title Slide Hepatocellular Carcinoma (HCC) Professor Muhammad Umar MBBS, MCPS, FCPS (PAK), FACG (USA), FRCP (L), FRCP (G), ASGE-M(USA), AGAF (USA) Chair & Professor of Medicine Rawalpindi Medical College
More informationWorldwide Causes of HCC
Approach to HCV Treatment in Patients with HCC Mark W. Russo, MD, MPH, FACG Carolinas HealthCare System Charlotte Worldwide Causes of HCC 60% 50% 40% 30% 20% 10% 0% 54% 31% 15% Hepatitis B Hepatitis C
More informationAASLD Washington DC, USA Dr. Alexander Kim Chief Vascular and Interventional Radiology, Medstar Georgetown University Hospital
AASLD 2017 - Washington DC, USA Dr. Alexander Kim Chief Vascular and Interventional Radiology, Medstar Georgetown University Hospital THE CHANGING LANDSCAPE IN THE TREATMENT OF HCC DISCLAIMER Please note:
More information3 Workshop on HCV THERAPY ADVANCES New Antivirals in Clinical Practice
3 Workshop on HCV THERAPY ADVANCES New Antivirals in Clinical Practice Rome, 13 December 2013 Management and monitoring of HCC in the future era of DAA s Prof. Massimo Colombo Chairman Department of Liver,
More informationOHSU Digital Commons. Oregon Health & Science University. Barry Schlansky. Scholar Archive. July 2013
Oregon Health & Science University OHSU Digital Commons Scholar Archive July 2013 Waitlist time predicts survival after liver transplantation for hepatocellular carcinoma : a cohort study in the United
More informationLiver Transplantation for Hepatocellular Carcinoma: An Appraisal of Current Controversies
2235-1795/0014-0183$38.00/0 183 Review Liver Transplantation for Hepatocellular Carcinoma: An Appraisal of Current Controversies Yee Lee Cheah a Pierce K.H. Chow b,c,d a Hepatobiliary and Pancreatic Surgery,
More informationCopyright Lippincott Williams & Wilkins. Unauthorized reproduction of this article is prohibited.
Original article 553 Serum levels of preoperative a-fetoprotein and CA19-9 predict survival of hepatic carcinoma patients after liver transplantation Ping Wan, Jianjun Zhang, Xidai Long, Qigen Li, Ning
More informationSurgical management of HCC. Evangelos Prassas Hepatobiliary and Pancreatic Surgery / Liver Transplantation Kings College Hospital / London
Surgical management of HCC Evangelos Prassas Hepatobiliary and Pancreatic Surgery / Liver Transplantation Kings College Hospital / London Global distribution of HCC and staging systems WEST 1. Italy (Milan,
More informationAdvances in percutaneous ablation for hepatocellular carcinoma
Advances in percutaneous ablation for hepatocellular carcinoma P. Nahon1,2,3 1 Hepatology, Jean Verdier Hospital, APHP, Bondy, France 2 Paris 13 university, Sorbonne Paris Cité, UFRSMBH, Bobigny, France
More informationSelection Criteria and Insertion of SIRT into HCC Treatment Guidelines
Selection Criteria and Insertion of SIRT into HCC Treatment Guidelines 2 nd Asia Pacific Symposium on Liver- Directed Y-90 Microspheres Therapy 1st November 2014, Singapore Pierce Chow FRCSE PhD SIRT in
More information